On the other hand, we observed that CDK4/6 inhibitors, whose mechanism of action is linked to decreased E2F target activity, have received FDA approval and are being used to treat breast cancer.[34, 35] Thus, we gathered blood samples from fifteen breast cancer patients both before and after therapy with CDK4/6 inhibitors. This evidence concerns the gene CDK4 and breast carcinoma.